Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.39 |
| ▸ | GLP1R | P43220 | 5/20 | 0.38 |
| ▸ | SCTR | P47872 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | TFPI | P10646 | 1/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555524 | 0.89 | OPRD1 (0.41) | OPRM1OPRD1OPRK1PSMB8PSMB9 | |
| SCHEMBL29824489 | 0.87 | OPRD1 (0.37) | OPRM1OPRD1OPRK1GLP1RSCTR | |
| SCHEMBL29554598 | 0.87 | REN (0.37) | OPRD1PSMB8PSMB9PSMB5CCKAR | |
| SCHEMBL31210152 | 0.86 | PSMB8 (0.37) | OPRM1OPRD1OPRK1GLP1RSCTR | |
| SCHEMBL31088668 | 0.85 | REN (0.36) | OPRM1OPRD1PSMB8PSMB9PSMB5 | |
| SCHEMBL30175817 | 0.84 | OPRM1 (0.40) | OPRM1OPRD1OPRK1GLP1RSCTR | |
| SCHEMBL30242087 | 0.84 | OPRM1 (0.42) | OPRM1OPRD1OPRK1GLP1RSCTR | |
| SCHEMBL31461628 | 0.83 | OPRM1 (0.45) | OPRM1OPRD1OPRK1GLP1RSCTR | |
| SCHEMBL31461629 | 0.83 | GLP1R (0.43) | OPRM1OPRD1OPRK1GLP1RSCTR | |
| SCHEMBL30175807 | 0.82 | REN (0.39) | OPRM1OPRD1OPRK1GLP1RSCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112791178-B | GLP-1R/GCGR dual agonist polypeptide derivatives for preventing or treating renal fibrosis | 深圳市图微安创科技开发有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114585640-B | GLP-1R/GCGR double-target agonist polypeptide derivative for treating liver fibrosis related to viral hepatitis | 深圳市图微安创科技开发有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-114920818-B | Treatment of biliary cirrhosis based on oxyntomodulin analog GLP-1R/GCGR dual-target agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-111372945-B | Treatment of idiopathic pulmonary interstitial fibrosis based on oxyntomodulin analog GLP-1R/GCGR dual-target agonist polypeptides | 中山大学 | 2024-02-02 | — | — | CN | disclosed |
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| CN-106046145-B | GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis | 深圳市图微安创科技开发有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115181175-A | GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis | 深圳市图微安创科技开发有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | SHENZHEN TURIER BIOTECH CO., LTD. | 2022-08-23 | — | — | US | disclosed |
| CN-114920818-A | Treatment of biliary cirrhosis based on oxyntomodulin analog GLP-1R/GCGR dual-target agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-111278853-B | Treatment of biliary cirrhosis based on oxyntomodulin analog GLP-1R/GCGR dual-target agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114585640-A | GLP-1R/GCGR double-target agonist polypeptide derivative for treating viral hepatitis-related liver fibrosis | 深圳市图微安创科技开发有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022061924-A1 | GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE DERIVATIVES FOR TREATMENT OF VIRAL HEPATITIS-RELATED HEPATIC FIBROSIS | 深圳市图微安创科技开发有限公司 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | GCGR, GLP1R, GIPR | OPRM1 897/4885OPRD1 790/4885OPRK1 693/4885 |
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | GLP1R, GCGR, GIPR | OPRM1 3338/4885OPRD1 2819/4885OPRK1 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.